---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091777"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:18:06.509118+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q2 revenue up 6% to $44.5M, net loss widens to $0.34/share, reaffirms FY guidance

## Summary
- Revenue $44.5M (+6% YoY); gross margin 80.2% vs 81.7% prior year.
- Net loss ($21.2M) or ($0.34)/share vs ($12.3M) or ($0.20)/share in Q2 2023.
- Adjusted EBITDA loss ($8.7M) vs ($7.7M) a year ago; cash & equivalents $97.0M.
- Full-year 2024 revenue guidance reaffirmed at $201M-$211M (7-13% growth); Adj. EBITDA expected to improve ~50%.
- CEO highlights planned entry into minimally invasive metatarsal osteotomy market in Q4 2024 and 65 granted U.S. patents.

## SEC filing metadata
- accession: 0000950170-24-091777
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017024091777/0000950170-24-091777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017024091777/tmci-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091777
- JSON: https://secwatch.observer/filing/0000950170-24-091777.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091777.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.